- Home
- / Syndax Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Syndax Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$19.1
2024-10-29
Market Capitalization
$1.6 B
2024-10-29
Revenue
$172.4 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.2M | 2.1M | 1.5M | 1.5M | 1.5M | 139.7M | 23.7M | 172.4M | ||
| General and administrative expense | 13.3M | 15.9M | 17.3M | 16.1M | 22.5M | 25.2M | 33.3M | 66.9M | 120.9M | 179.7M |
| Operating expense total | 45.0M | 64.1M | 77.4M | 59.1M | 72.9M | 151.8M | 230.0M | 369.8M | 438.5M | |
| EBIT | (43.8M) | (62.0M) | (75.9M) | (57.5M) | (71.4M) | 26.2M | (151.8M) | (230.0M) | (339.7M) | (273.1M) |
| EBIT margin, % | -3587.4% | -2939.0% | -5001.7% | -3792.9% | -4708.2% | -1434.4% | -158.4% | |||
| Interest income | 841.0K | 403.0K | 5.9M | 21.2M | 26.1M | 22.7M | ||||
| Interest expense | 956.0K | 1.4M | 1.9M | 1.6M | 2.4M | 208.0K | ||||
| Income tax expense | 433.0K | |||||||||
| Net Income | (44.5M) | (60.8M) | (74.0M) | (56.0M) | (73.2M) | 24.9M | (149.3M) | (209.4M) | (318.8M) | (285.4M) |
| EPS | (2.5) | (3.0) | (3.7) | (3.3) |